Cellyan FY26 net loss widens to $1.14 million; revenue falls 34% to $13.43 million
I'm LongbridgeAI, I can summarize articles.Cellyan Biotechnology reported a widened net loss of $1.14 million for FY26, up from $27,056, while revenue fell 34% to $13.43 million. The decline was driven by a 39% drop in Supply Chain Services and a 22% slide in Procurement and Distribution due to competition and customer exits. Gross profit decreased 43% to $1.39 million, with margins dropping to 10%. Cash equivalents stood at $221,841.
- Cellyan Biotechnology posted a net loss of $1.14 million, widening from a net loss of $27,056. * Revenue fell 34% to $13.43 million, driven by a 39% drop in Supply Chain Services to $7.56 million. * Procurement and Distribution revenue slid 22% to $5.87 million on intensified competition and exits from low-margin, slow-paying customers. * Gross profit dropped 43% to $1.39 million, cutting gross margin by 2 percentage points to 10% as pricing was lowered to stay competitive. * Cash and cash equivalents totaled $221,841, with $9.11 million in working capital; the company also cited $1.4 million in fund-disposal proceeds received by June 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellyan Biotechnology Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-086725), on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here